Quality control trial for human immunodeficiency virus type 1 drug resistance testing using clinical samples reveals problems with detecting minority species and interpretation of test results

Journal of Clinical Microbiology

Volumn 41, Issue 8, 2003, Pages 3559-3565

  Korn, Klaus ^a   Reil, Heide ^a   Walter, Hauke ^a   Schmidt, Barbara ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; QUALITY CONTROL; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; BASE SEQUENCE; DNA PRIMERS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0042023525     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.41.8.3559-3565.2003     Document Type: Article

References (22)

1. De Mendoza, C., O. Gallego, L. Valer, and J. Gonzalez-Lahoz. 2001. Update on genotype-guided antiretroviral therapy. AIDS Rev. 3:208-215.
2. EuroGuidelines Group for HIV Resistance. 2001. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS 15:309-320.
3. Hertogs, K., S. Bloor, V. De Vroey, C. van Den Eynde, P. Dehertogh, A. van Cauwenberge, M. Sturmer, T. Alcorn, S. Wegner, M. van Houtte, V. Miller, and B. A. Larder. 2000. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrob. Agents Chemother. 44:568-573.
4. Hirsch, M. S., F. Brun-Vezinet, R. T. D'Aquila, S. M. Hammer, V. A. Johnson, D. R. Kuritzkes, C. Loveday, J. W. Mellors, B. Clotet, B. Conway, L. M. Demeter, S. Vella, D. M. Jacobsen, and D. D. Richman. 2000. Antiretroviral drug resistance testing in adult HIV-1 infection recommendations of an International AIDS Society-USA Panel. JAMA 283:2417-2426.
5. Kellam, P., and B. A. Larder. 1994. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 38:23-30.
6. Larder, B. A., S. D. Kemp, and R. Harrigan. 1995. Potential mechanism of sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
7. Means, R. E., T. Greenough, and R. C. Desrosiers. 1997. Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus. J. Virol. 69:5431-5436.
8. Newton, C. R., A. Graham, L. E. Heptinstall, S. J. Powell, C. Summers, N. Kalsheker, J. C. Smith, and A. F. Markham. 1989. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 17:2503-2516.
9. Race, E., E. Dam, V. Obry, S. Paulous, and F. Clavel. 1999. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. AIDS 13:2061-2068.
10. Schinazi, R. F., B. Larder, and J. W. Mellors. 2000. Mutations in retroviral genes associated with drug resistance: 2000-2001 update. Int. Antiviral News 8:65-92.
11. Schmidt, B., H. Walter, and K. Korn. 2002. Genotypic drug resistance interpretation systems: the cutting edge of antiretroviral therapy. AIDS Rev. 4:148-156.
12. Schmit, J. C., L. Ruiz, L. Stuyver, K. Van Laethem, I. Vanderlinden, T. Puig, R. Rossau, J. Desmyter, E. De Clercq, B. Clotet, and A. M. Vandamme. 1998. Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations. J. Virol. Methods 73:77-82.
13. Schuurman, R., D. Brambilla, T. de Groot, D. Huang, S. Land, J. Bremer, I. Benders, C. A. Boucher, et al. 2002. Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. AIDS Res. Hum. Retrovir 18:243-248.
14. Schuurman, R., L. Demeter, P. Reichelderfer, J. Tijnagel, T. de Groot, and C. Boucher. 1999. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J. Clin. Microbiol. 37:2291-2296.
15. Shafer, R. W., D. R. Jung, and B. J. Betts. 2000. Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries. Nat. Med. 6:1290-1292.
16. Tisdale, M., S. D. Kemp, N. R. Parry, and B. A. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5653-5656.
17. Vandamme, A. M., F. Houyez, D. Banhegyi, B. Clotet, C. De Schrijver, K. A. De Smet, W. W. Hall, R. Harrigan, N. Hellmann, K. Hertogs, C. Holtzer, B. Larder, D. Pillay, E. Race, J. C. Schmit, R. Schuurman, E. Schulse, A. Sonnerborg, and V. Miller. 2001. Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up. Antiviral Ther. 6:21-39.
18. Walter, H., B. Schmidt, K. Korn, A. M. Vandamme, T. Harrer, and K. Überla. 1999. Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. J. Clin. Virol. 13:71-80.
19. Weinstein, M. C., S. J. Goldie, E. Losina, C. J. Cohen, J. D. Baxter, H. Zhang, A. D. Kimmel, and K. A. Freedberg. 2001. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann. Intern. Med. 134:440-450.
20. Wensing, A. M., W. Keulen, M. Buimer, D. Brambilla, R. Schuurman, and C. Boucher. 2002. Analysis of the world-wide evaluation study on HIV-1 genotype interpretation; ENVA-3. Antiviral Ther. 6(Suppl. 1):101.
21. Yeni, P. G., S. M. Hammer, C. C. Carpenter, D. A. Cooper, M. A. Fischl, J. M. Gatell, B. G. Gazzard, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. Montaner, D. D. Richman, M. S. Saag, M. Schechter, R. T. Schooley, M. A. Thompson, S. Vella, and P. A. Volberding. 2002. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 288:222-235.
22. Ziermann, R., K. Limoli, K. Das, E. Arnold, C. J. Petropoulos, and N. T. Parkin. 2000. A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir. J. Virol. 74:4414-4419.